### Additional File 6
Comparison of vaccinated patients with a matched cohort

<table>
<thead>
<tr>
<th>FIGO</th>
<th>Vaccine group (n=16)</th>
<th>Matched cohort (n=16)</th>
<th>Independent Sample T-test for equality of means (p=; 95% CI)</th>
<th>Significance (p=)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD (range)</td>
<td>Mean ± SD (range)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1B1</td>
<td>6 (37.5%)</td>
<td>6 (37.5%)</td>
<td></td>
<td>1.0*</td>
</tr>
<tr>
<td>1B2</td>
<td>1 (6.2%)</td>
<td>1 (6.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2A</td>
<td>2 (12.5%)</td>
<td>2 (12.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2B</td>
<td>3 (18.8%)</td>
<td>3 (18.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3B</td>
<td>2 (12.5%)</td>
<td>2 (12.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2 (12.5%)</td>
<td>2 (12.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval diagnosis - recurrence (months)</td>
<td>16.06 ± 12.2</td>
<td>14.25 ± 9.2</td>
<td>0.83 95% CI (-8.60 - 6.98)</td>
<td>0.833***</td>
</tr>
</tbody>
</table>

**Primary Therapy**

- None: 1 (6.2%)
- Surgery: 7 (43.8%)
- CHRT: 8 (50%)
- RT: 0

**Recurrence Therapy**

- Vaccination (Vac): 10 (62.5%)
- CH + Vac: 2 (12.5%)
- Vac + CH + RT: 1 (6.2%)
- Vac + RT: 1 (6.2%)
- CH + Vac + CH: 1 (6.2%)
- SUR + Vac: 1 (6.2%)
- CH: 0
- CHRT: 0
- SUR: 0
- SUR + CH: 0
- SUR + CHRT: 0
- SUR + RT: 0
- RT: 0
- None: 0

**Age diagnosis (years)**

- 42.88 ± 9.6
- 40.19 ± 7.7

**Age recurrence (years)**

- 44.25 ± 9.57
- 41.56 ± 7.4

**Recurrence**

- Endstage: 1 (6.2%)
- LR: 4 (25%)
- Distance: 11 (68.8%)

**Primary Chemotherapy**

- None: 5 (31.2%)
- Unknown: 1 (6.2%)
- Cisplatin: 9 (56.2%)
- Carboplatin/Taxol: 0
- Carboplatin/Cisplatin: 1 (6.2%)

**Recurrence Chemotherapy**

- None: 13 (81.2%)
- Cisplatin: 0
- Cisplatin/Topotecan: 1 (6.2%)
- Carboplatin/Taxol: 2 (12.5%)
- Cisplatin/Taxol: 0
- Unknown: 0

**Adjuvant Therapy**

- None: 8 (50%)
- RT: 2 (12.5%)
- CHRT: 3 (18.8%)
- SUR: 3 (18.8%)
- HT: 0

**Survival after recurrence (months)**

- 12.81 ± 9.4
- 11.44 ± 7.7

**Dead (number of patients)**

- 15 (83.8%)

Indicated p-values were generated via the Mann-Whitney non-parametric independent t-test, by Chi-Square test when indicated with a (*), by Wilcoxon Signed Rank test (**) or by parametric T-test (***)